Compare AbbVie Inc (ABBV) vs Intuit Inc. (INTU) Price & Performance

AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.

The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.

Intuit (INTU) trades at $272.14, down 1.17% on the day, amid a bearish technical signal and ongoing securities fraud investigations. The stock shows strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $12.80 versus $12.57 expected, and robust profitability with a net income margin of 21.91%. Revenue growth is steady, climbing from $12.7B in 2022 to $18.8B in 2025, supported by a high gross profit margin of 79.96%.

Despite solid fundamentals, INTU faces significant headwinds from legal scrutiny and negative sentiment, with a 20% stock drop triggering multiple fraud probes. Analyst consensus remains bullish with a $433.69 price target, but near-term risks from litigation and competitive pressures in tax software could limit upside. The stock's current valuation at a P/E of 16.6 offers a margin of safety if growth persists.